Nobabelle (Ethinylestradiol, Gestodene)

Ethinyloestradiol mimics natural estrogen, while gestodene acts as a progestogen. Together they suppress the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, preventing ovulation. The progestogenic component also thickens cervical mucus and alters the endometrium, creating conditions that are unfavorable for fertilisation and implantation.

The dosing regimen for Nobabelle is determined by the prescribing clinician. Typically, combined oral contraceptives are taken once daily for a defined cycle, but the exact schedule, tablet strength, and duration should be individualized based on the patient’s medical history and the prescriber’s judgment.

Nobabelle is intended for use only when pregnancy is not desired. It should be discontinued if pregnancy occurs. Safety data for use during pregnancy are not applicable, and the product is generally not recommended while breastfeeding without medical advice, as hormonal exposure may affect milk production and infant exposure.

To request Nobabelle, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Nobabelle contains ethinyloestradiol and gestodene, a low‑dose estrogen‑progestogen combination that offers a favorable efficacy‑to‑side‑effect profile. Compared with products that use higher‑dose estrogen or different progestins, Nobabelle may present a lower risk of estrogen‑related adverse events while maintaining comparable contraceptive effectiveness.

Nobabelle tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Nobabelle is taken orally, usually once daily at the same time each day. The tablets are swallowed with water and are not to be split, crushed, or chewed unless otherwise directed by a healthcare professional.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), and severe hypertension. Women with a history of clotting disorders, smoking, or certain cardiovascular conditions should be evaluated carefully before use.

Nobabelle is contraindicated in women with known or suspected pregnancy, active or history of thromboembolic disease, uncontrolled hypertension, certain liver tumors, or those who are breastfeeding without medical guidance. It should also be avoided in individuals with a known hypersensitivity to ethinyloestradiol, gestodene, or any excipients in the tablet.